GLAUKOS price to free cash flow GKOS

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 165×; Feb 2020
10-year median: 176×
10-year range: 38.5× to 491×
Peer median: 18.5×

GLAUKOS' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2020, at 165×.

On the days it had one over the last ten years, its median was 176×, from 38.5× in Aug 2017 to 491× in Oct 2016.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2020	165×	165×	253×
2019	206×	124×	339×
2018	223×	50.0×	263×
2017	85.2×	38.5×	403×
2016	299×	279×	496×

Against its peers

Companies in Medical - Instruments & Supplies nearest GLAUKOS' size, closest first, today.

Company	Price to free cash flow
GKOSGLAUKOS	n/m
PODDInsulet	35.2×
GMEDGlobus Medical	14.5×
ALGNAlign Technology	17.3×
COOCooper Companies	17.2×
PENPenumbra	59.2×
SOLVSolventum	n/m
MSAMSA Safety	19.8×
MMSIMerit Medical Systems	27.4×
HAEHaemonetics	18.5×
VNTVontier	12.1×
Peer median	18.5×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on GLAUKOS

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.